Cosmo Bio Company,Limited
3386.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.59 | -0.87 | -0.38 | 0.79 |
| FCF Yield | 0.40% | 11.10% | 3.07% | 7.51% |
| EV / EBITDA | 8.61 | 3.65 | 3.06 | 2.78 |
| Quality | ||||
| ROIC | 2.20% | 3.76% | 6.14% | 8.15% |
| Gross Margin | 33.17% | 34.80% | 36.02% | 39.64% |
| Cash Conversion Ratio | 0.92 | 1.13 | 0.55 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.66% | 0.39% | 5.69% | 6.74% |
| Free Cash Flow Growth | -96.07% | 253.33% | -64.50% | -31.30% |
| Safety | ||||
| Net Debt / EBITDA | -5.22 | -3.50 | -3.24 | -2.56 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 6.30 | 5.87 | 5.39 | 6.46 |
| Cash Conversion Cycle | 126.47 | 135.33 | 140.41 | 124.91 |